Fresenius Kabi Compounding Canton, MA

Size: px
Start display at page:

Download "Fresenius Kabi Compounding Canton, MA"

Transcription

1 Fresenius Kabi Compounding Canton, MA

2 Fresenius Kabi - Boston Compounding Andy Basso Operations Director

3 Agenda Existential question: Why am I here? Who is Fresenius-Kabi? What does our Canton Facility do? Why we are building a Compounding Facility? How do we reduce waste water usage? Questions/Wrap-up Copyright Fresenius Kabi AG

4 The Fresenius Group Fresenius Medical Care Fresenius Kabi Fresenius Helios Fresenius Vamed Dialysis Equipment and Services Infusion Therapies Transfusion Therapies I.V. Drugs Clinical Nutrition Medical Devices Aseptic Compounding Sales 2016 Hospital Operations Engineering and Services for Health Care Facilities $17.9b 6.0b 5.8b 1.2b Fresenius SE is a global health care group based in Frankfurt Germany, with annual sales of 29b and more than 260,000 employees (2017) Recently acquired 4.5b Akorn and Merck Biologics (Germany) Copyright Fresenius Kabi 4

5 What is Compounding? Allows physicians to prescribe a very specific medication for a patient's individual needs Allergy Dosage form Established tradition 80% of prescriptions were compounded until the 1920 s Decreased with modern pharmaceutical manufacturing Still done by Nurses, Doctors, Pharmacists Medication errors Less efficient / expensive Why Commercially Compound? Provides convenience for high volume product With increase of regulations, smaller facilities cannot meet the requirements Copyright Fresenius Kabi AG

6 What is Drug Compounding? IV DRUG COMPOUNDING PN COMPOUNDING Lyophilized Drugs Liquid Drugs Single components 3-Chamber bag Liquid Product Manual or automated preparation (e.g. reconstitution, dilution, transfer) Mix of various components Manual or automated volume delivery Final compounded product in a syringe, bag or device to administer to the patient in the hospital or at home Final compounded product in a bag to feed the patient in the hospital or at home 6

7 IV Drug Compounding Process Example 1. Incoming approved Drug Product 2. Pool finished drug product into pooling bag and either: a) Dose into Diluent bags b) Dilute then fill c) Direct fill to empty syringe *NaCl or Dextrose 3. Visual inspect & Label 5. Package & Ship 4. QC test and release Copyright Fresenius Kabi AG

8 Compounding Evolution Pharmacy Compounding has come a long way from the past 8

9 Fresenius Kabi Compounding Experience Fresenius Kabi Centers Worldwide Overview Copyright Fresenius Kabi AG Canada Calgary Hamilton Montréal Toronto (x2) Vancouver Colombia Bogota Chile Santiago Concepción USA Boston UK Runcorn Argentina Buenos Aires Córdoba Norway Halden Brazil Rio de Janeiro São Paulo Germany Munich South Africa Johannesburg 18 locations >1,000 employees All compounded therapies Oncology Anti-infectives Anesthesia Nutrition Other IVs Copyright Fresenius Kabi AG 9

10 Need for Regulation New England Compounding Center incident 2012 Previous regulation Contaminated methylprednisolone Steroid injections > 700 cases of fungal meningitis and > 76 fatalities New Drug Safety Act 2013 created new compounder category Outsourcing Facilities in Section 503B FD&C Act Require drug manufacturing GMP quality standards FDA licensed and inspected 10

11 Waste Water Reduction Handwashing Stations Removes 99.98% of Dangerous Pathogens Full wash and rinse all in one 12 Second Standardized and Controlled Handwash Fast ROI by reducing labor time, water, and waste by 75% Guaranteed High Quality Handwash Every Time for Every User 11

12 Waste Water Reduction Instead of making RODI or WIFI for cleaning Instead of making saline or dextrose solutions we buy them We buy them 12

13 Waste Water Reduction Cleaning System Utilizing EXACT volume Balance of solutions evaporate 13

14 Waste Water Reduction Vapor Hydrogen Peroxide Disinfection A DRY Process 14

15 Waste Water Reduction Waste Stream 3 drums every Quarter Solid, Aqueous, Solvent 15

16 Waste Water Reduction Waste Stream Labs RODI, 2 dish washers Limestone tank 16

17 Questions? Thank you 17

Testimony of Molly Ventrelli Vice President, Regulatory Affairs Fresenius Kabi USA, LLC

Testimony of Molly Ventrelli Vice President, Regulatory Affairs Fresenius Kabi USA, LLC Testimony of Molly Ventrelli Vice President, Regulatory Affairs Fresenius Kabi USA, LLC U.S. House of Representatives Energy and Commerce Committee Subcommittee on Health Subcommittee January 30, 2018

More information

FORWARD THINKING HEALTHCARE

FORWARD THINKING HEALTHCARE AT A 2018 GLANCE 02 FORWARD THINKING HEALTHCARE Fresenius is a global healthcare group offering high-quality products and services for dialysis, hospitals, and outpatient treatment. With over 270,000 employees

More information

WHAT S NEXT FOR STERILE CONTRACT MANUFACTURING IN EMERGING MARKETS?

WHAT S NEXT FOR STERILE CONTRACT MANUFACTURING IN EMERGING MARKETS? WHAT S NEXT FOR STERILE CONTRACT MANUFACTURING IN EMERGING MARKETS? Dr. Laura Pandolfi Business Development Manager Product Partnering Sterile Pharmaceuticals Region Europe, LAM, Africa & Asia CPhI woldwide

More information

Ghalib Abbasi, RPh, MS, PharmD Pharmacy Technology Consultant Florida, USA

Ghalib Abbasi, RPh, MS, PharmD Pharmacy Technology Consultant Florida, USA Ghalib Abbasi, RPh, MS, PharmD Pharmacy Technology Consultant Florida, USA Disclosure Information IV Robotics and Workflow: Design and Integration with other Healthcare and Regulatory Components Ghalib

More information

An ExampleOf Visual SixSigma, with JMP Scripting at Fresenius Kabi plant Cavezzo - Italy

An ExampleOf Visual SixSigma, with JMP Scripting at Fresenius Kabi plant Cavezzo - Italy An ExampleOf Visual SixSigma, with JMP Scripting at Fresenius Kabi plant Cavezzo - Italy JMP DiscoverySummit 2015, Brussels, 25 March 2015 Copyright Fresenius Kabi AG 1 The Fresenius Group Fresenius Medical

More information

CGMP Requirements for Investigational Products

CGMP Requirements for Investigational Products PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health

More information

Capital Market Day June 12, 2012

Capital Market Day June 12, 2012 Capital Market Day 2012 June 12, 2012 Product Segments IV Drugs John Ducker Member of the Management Board President Region North America Capital Market Day Fresenius Kabi, June 12, 2012 Agenda 1 2 3 4

More information

FDA Update on Compounding

FDA Update on Compounding FDA Update on Compounding Julie Dohm, JD, PhD Senior Science Advisor for Compounding, Center for Drug Evaluation and Research; Agency Lead on Compounding, FDA Compounding A Snapshot Compounded drugs: Are

More information

Pharmacy. Medication. Checks

Pharmacy. Medication. Checks Pharmacy Medication Checks Module 2 Table of Contents Section A... 1 A.1 Clinical Medication Order Check... 1 A.2 Final Product and Computer Order Entry Check... 1 Section B... 2 B.1 Documentation of Pharmacy

More information

Supply of aseptically - prepared doses of IMPs across legal boundaries. Edition 1. December 2017

Supply of aseptically - prepared doses of IMPs across legal boundaries. Edition 1. December 2017 Supply of aseptically - prepared doses of IMPs across legal boundaries Edition 1 December 2017 Endorsed and supported by: NHS Pharmaceutical Quality Assurance Committee 2017 with National Pharmacy Clinical

More information

Fresenius makes excellent start to 2018, with strong sales and net income growth in constant currency

Fresenius makes excellent start to 2018, with strong sales and net income growth in constant currency Investor News Markus Georgi Senior Vice President Investor Relations Fresenius SE & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg Germany T +49 6172 608-2485 F +49 6172 608-2488 markus.georgi@fresenius.com

More information

Advancing the Delivery of Home Infusion Therapy curlinpump.com

Advancing the Delivery of Home Infusion Therapy curlinpump.com Advancing the Delivery of Home Infusion Therapy curlinpump.com Innovative, multi-therapy pump designed for more precise and efficient infusions Home healthcare and drug advancements place new demands on

More information

The generics environment today

The generics environment today The generics environment today Sergio Napolitano EGA Director Legal Affairs and Trade 2 October 2015, Warsaw C O M PA N I E S N AT I O N A L A S S O C I AT I O N S EGA Membership GE (Hungary) SPMA (Slovenia)

More information

Microbiological Quality of Drug Products after Penetration of the Container System for Dose Preparation Prior to Patient Administration

Microbiological Quality of Drug Products after Penetration of the Container System for Dose Preparation Prior to Patient Administration Microbiological Quality of Drug Products after Penetration of the Container System for Dose Preparation Prior to Patient Administration John W. Metcalfe, Ph.D. Senior Review Microbiologist FDA/CDER/OPS/New

More information

Health Care Worldwide. Crédit Suisse Global Credit Products Conference October 1, Barcelona

Health Care Worldwide. Crédit Suisse Global Credit Products Conference October 1, Barcelona Health Care Worldwide Crédit Suisse Global Credit Products Conference October 1, 2015 - Barcelona Safe Harbor Statement This presentation contains forward-looking statements that are subject to various

More information

A Leading Global Health Care Group

A Leading Global Health Care Group A Leading Global Health Care Group Roadshow Benelux June 29/30, 2015 For detailed financial information please see our annual/quarterly reports and/or conference call materials on www.fresenius.com/ir.

More information

Health Care Worldwide. Bank of America, 2007 Health Care Conference, May 30, 2007

Health Care Worldwide. Bank of America, 2007 Health Care Conference, May 30, 2007 Health Care Worldwide Bank of America, 2007 Health Care Conference, May 30, 2007 1 Fresenius This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future

More information

SUPPLY CHAIN CENTER ACUTE CARE PHARMACY

SUPPLY CHAIN CENTER ACUTE CARE PHARMACY SUPPLY CHAIN CENTER ACUTE CARE PHARMACY FIVE YEARS EXPERIENCE IN A CENTRALIZED STERILE COMPOUNDING SERVICE WITH THE RIVA IV AUTOMATION SYSTEM INTERMOUNTAIN HEALTHCARE THE VISION FOR STERILE COMPOUNDING

More information

How Logistics Enables the Healthcare Revolution. Richard Holmes Managing Director of Polar Speed Distribution Ltd, a UPS company

How Logistics Enables the Healthcare Revolution. Richard Holmes Managing Director of Polar Speed Distribution Ltd, a UPS company How Logistics Enables the Healthcare Revolution Richard Holmes Managing Director of Polar Speed Distribution Ltd, a UPS company Introduction There is a revolution taking place in healthcare delivery. Patient-centred

More information

Overview. A brief from

Overview. A brief from A brief from Dec 2017 Getty Images What Are Compounded Drugs, and How Can They Be Kept Safe? Drug Quality and Security Act plays key role in important but potentially high-risk aspect of health care Overview

More information

Fresenius Investor News

Fresenius Investor News health care worldwide October 31, 2006 Contact: Birgit Grund Fresenius AG Investor Relations Tel. ++49-6172 - 608 2485 Fax ++49-6172 - 608 2488 e-mail: ir-fre@fresenius.de Internet: www.fresenius-ag.com

More information

Compounding Questions and Answers

Compounding Questions and Answers Compounding Questions and Answers JANUARY 10, 2011 1. Question: What is a reliable supplier? Answer: Some examples of reliable suppliers are FDA licensed manufacturers, CA Department of Public Health Food

More information

Quarterly Financial Report of Fresenius Group

Quarterly Financial Report of Fresenius Group Quarterly Financial Report of Fresenius Group applying International Financial Reporting Standards (IFRS) 1 st Half and 2 nd Quarter 2018 2 TABLE OF CONTENTS 3 Fresenius Group figures at a glance 5 Fresenius

More information

Purchasing for Safety Policy for Pharmaceuticals January Page 1 of 8 (Purchasing for Safety Policy for Pharmaceuticals)

Purchasing for Safety Policy for Pharmaceuticals January Page 1 of 8 (Purchasing for Safety Policy for Pharmaceuticals) Purchasing for Safety Policy for s January 2010 Page 1 of 8 (Purchasing for Safety Policy for s) Policy Title Purchasing for Safety Policy for s Policy Reference Number Acute10/006 Implementation Date

More information

Excellent sales and earnings growth Earnings outlook raised

Excellent sales and earnings growth Earnings outlook raised Press Release August 3, 2010 Matthias Link Corporate Communications Fresenius SE Else-Kröner-Straße 1 61352 Bad Homburg Germany T +49 6172 608-2872 F +49 6172 608-2294 Matthias.Link@fresenius.com www.fresenius.com

More information

I. Purpose. II. Definitions. Last Approval Date

I. Purpose. II. Definitions. Last Approval Date Investigational Drugs and Biologics Page 1 of 13 I. Purpose The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics

More information

Innovative H 2 O 2 V-Phase biodecontamination solutions

Innovative H 2 O 2 V-Phase biodecontamination solutions Innovative H 2 O 2 V-Phase biodecontamination solutions ENEMY ZERO H 2 O 2 V-Phase = 6 Log reduction The right solution to eliminate a wide spectrum of microorganisms quickly and effectively. The presence

More information

A Leading Global Health Care Group

A Leading Global Health Care Group A Leading Global Health Care Group Roadshow Copenhagen October 6, 2015 For detailed financial information please see our annual/quarterly reports and/or conference call materials on www.fresenius.com/ir.

More information

Quarterly Financial Report of Fresenius Group

Quarterly Financial Report of Fresenius Group Quarterly Financial Report of Fresenius Group applying International Financial Reporting Standards (IFRS) 1 st 3 rd Quarter and 3 rd Quarter 2017 2 TABLE OF CONTENTS 3 Fresenius Group figures at a glance

More information

A Leading Global Health Care Group

A Leading Global Health Care Group A Leading Global Health Care Group Frankfurt stock exchange: FRE US ADR program: FSNUY www.fresenius.com/investors General Presentation, Fresenius SE & Co. KGaA, Investor Relations Copyright, August 2016

More information

Fresenius reports 15th consecutive record year Significant investments into medium-term growth in FY/18 and FY/19 Healthy medium-term growth targets

Fresenius reports 15th consecutive record year Significant investments into medium-term growth in FY/18 and FY/19 Healthy medium-term growth targets Investor News February 20, 209 Markus Georgi Senior Vice President Investor Relations Fresenius SE & Co. KGaA Else-Kröner-Straße 6352 Bad Homburg Germany T +49 672 608-2485 F +49 672 608-2488 markus.georgi@fresenius.com

More information

Received: ; Accepted: HOME PARENTERAL NUTRITION IN STERILE PRODUCTS. SenthilKumar Krishnan *, D. R.Nagesh

Received: ; Accepted: HOME PARENTERAL NUTRITION IN STERILE PRODUCTS. SenthilKumar Krishnan *, D. R.Nagesh International Journal of Universal Pharmacy and Bio Sciences 1(2): November-December2012 INTERNATIONAL JOURNAL OF UNIVERSAL PHARMACY AND BIO SCIENCES Pharmaceutical Sciences Review Article!!! Received:

More information

Annual General Meeting of Fresenius SE & Co. KGaA on May 13, Speech of Dr. Ulf M. Schneider, Chairman of the Management Board

Annual General Meeting of Fresenius SE & Co. KGaA on May 13, Speech of Dr. Ulf M. Schneider, Chairman of the Management Board Annual General Meeting of Fresenius SE & Co. KGaA on May 13, 2016 Speech of Dr. Ulf M. Schneider, Chairman of the Management Board The spoken word has precedence. Good morning, ladies and gentlemen. On

More information

USP CHAPTER <797> INTRODUCTION RISK LEVELS

USP CHAPTER <797> INTRODUCTION RISK LEVELS USP CHAPTER INTRODUCTION RISK LEVELS Introduction: The objective of this chapter is to describe conditions and practices to prevent harm, including death, to patients that could result from 1) microbial

More information

Infection and Intravenous Drug Delivery: A Long and Tumultuous Relationship

Infection and Intravenous Drug Delivery: A Long and Tumultuous Relationship Infection and Intravenous Drug Delivery: A Long and Tumultuous Relationship Eric Wenzler, PharmD, BCPS, AAHVIP Assistant Professor University of Illinois at Chicago Disclosures I have no actual or potential

More information

Last Revised: 3/2018 Prior Version: 12/2014 SOP NUMBER: SS-304 Page 1 of 4

Last Revised: 3/2018 Prior Version: 12/2014 SOP NUMBER: SS-304 Page 1 of 4 STANDARD OPERATING PROCEDURE (SOP) FOR CLINICAL RESEARCH Title: Investigational Drug Billing Last Revised: 3/2018 Prior Version: 12/2014 SOP NUMBER: SS-304 Page 1 of 4 1. PURPOSE: To assure accurate and

More information

J.P. Morgan 37 th Annual Healthcare Conference

J.P. Morgan 37 th Annual Healthcare Conference J.P. Morgan 37 th Annual Healthcare Conference San Francisco, 7-8 January 2019 Frankfurt stock exchange: FRE US ADR program: FSNUY www.fresenius.com/investors Safe Harbor Statement This presentation contains

More information

AMENDED Draft Report of the Compounding Workgroup

AMENDED Draft Report of the Compounding Workgroup AMENDED Draft Report of the Compounding Workgroup This report summarizes the actions taken by a workgroup convened by the Board of Pharmacy pursuant to the enactment clause of HB 1035 passed during the

More information

Phase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017

Phase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 Phase Appropriate GMPs for IMPs Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 1 Lets start with References https://mhrainspectorate.blog.gov.uk/2016/0 5/20/manufacture-of-investigationalmedicinal-products-frequently-askedquestions/

More information

A LEADING GLOBAL HEALTH CARE GROUP. Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY

A LEADING GLOBAL HEALTH CARE GROUP. Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY A LEADING GLOBAL HEALTH CARE GROUP Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY www.fresenius.com/investors SAFE HARBOR STATEMENT This presentation contains forward-looking statements

More information

Quarterly Financial Report of Fresenius Group

Quarterly Financial Report of Fresenius Group Quarterly Financial Report of Fresenius Group applying International Financial Reporting Standards (IFRS) 1 st 3 rd Quarter and 3 rd Quarter 2018 2 TABLE OF CONTENTS 3 Fresenius Group figures at a glance

More information

100 YEARS OF FRESENIUS

100 YEARS OF FRESENIUS 6 100 Years of Fresenius 100 YEARS OF FRESENIUS 100 years ago, Dr. Eduard Fresenius set the cornerstone of our business. In the laboratory of his Frankfurt pharmacy he started a small pharmaceutical company

More information

Standard Operating Procedures

Standard Operating Procedures Standard Operating Procedures 5.14.1 Investigational Product Handling and Storage History Version Date Author Reason 1.1 23 rd August B Fazekas New procedure 2007 1.2 16 th October 2007 B Fazekas Update

More information

Case Study FARMACIA LUIS CORBÍ. The implementation of AuraPortal BPM has enabled Farmacia Luis Corbí to reduce delivery time from the

Case Study FARMACIA LUIS CORBÍ. The implementation of AuraPortal BPM has enabled Farmacia Luis Corbí to reduce delivery time from the The implementation of AuraPortal BPM has enabled Farmacia Luis Corbí to reduce delivery time from the unproductive time (acquiring reports, indicators, calls, consultations, etc.). Case Study FARMACIA

More information

Quarterly Financial Report of Fresenius Group

Quarterly Financial Report of Fresenius Group Quarterly Financial Report of Fresenius Group applying International Financial Reporting Standards (IFRS) 1 st 3 rd Quarter and 3 rd Quarter 2010 2 CONTENT 3 Fresenius Group figures at a glance 5 Fresenius

More information

Using Your Prescription. Drug Program. Answers to important questions about retail pharmacy and mail order purchasing

Using Your Prescription. Drug Program. Answers to important questions about retail pharmacy and mail order purchasing Using Your Prescription Drug Program Answers to important questions about retail pharmacy and mail order purchasing Welcome! We know you re going to enjoy the many advantages of your prescription drug

More information

Q1 3/2009: Strong organic sales growth achieved Outlook for 2009 fully confirmed

Q1 3/2009: Strong organic sales growth achieved Outlook for 2009 fully confirmed Investor News November 3, Birgit Grund Senior Vice President Investor Relations Fresenius SE Else-Kröner-Straße 1 61352 Bad Homburg Germany T +49 6172 608-2485 F +49 6172 608-2488 ir-fre@fresenius.com

More information

Sales and net income reach all-time highs 6% dividend increase proposed Positive Group outlook for 2015

Sales and net income reach all-time highs 6% dividend increase proposed Positive Group outlook for 2015 Investor News February 25, 205 Birgit Grund Senior Vice President Investor Relations Fresenius SE & Co. KGaA Else-Kröner-Straße 6352 Bad Homburg Germany T +49 672 608-2485 F +49 672 608-2488 birgit.grund@fresenius.com

More information

Inspection Trends. American Society for Quality Richmond, VA Section March 8, 2016

Inspection Trends. American Society for Quality Richmond, VA Section March 8, 2016 Inspection Trends American Society for Quality Richmond, VA Section March 8, 2016 Brooke K. Higgins, Senior Policy Advisor CDER / Office of Compliance Office of Manufacturing Quality Division of Drug Quality

More information

Compounding Pharmacy Assessment Questionnaire (CPAQ )

Compounding Pharmacy Assessment Questionnaire (CPAQ ) Compounding Pharmacy Assessment Questionnaire (CPAQ ) The International Academy of Compounding Pharmacists represents more than 2,700 pharmacists and other professionals who specialize in the provision

More information

Orange and Yellow Guides

Orange and Yellow Guides PHARMACY PREPARATION ACROSS EUROPE IS THERE A LEVEL PLAYING FIELD? Dr. Alison M.Beaney Regional Quality Assurance Specialist North-East England PHARMACY PREPARATION ACROSS EUROPE IS THERE A LEVEL PLAYING

More information

Your Perfect Match Innovative labels. Smart solutions.

Your Perfect Match Innovative labels. Smart solutions. Your Perfect Match Innovative labels. Smart solutions. Solutions Partner for the Pharmaceutical and Medical Device Industry Your Partner for Innovative Label Solutions Welcomes You! 1,000 employees generate

More information

Conference Call FY/17 Results

Conference Call FY/17 Results Conference Call FY/17 Results Bad Homburg, 27 February 2018 Frankfurt stock exchange: FRE US ADR program: FSNUY www.fresenius.com/investors Safe Harbor Statement This presentation contains forward-looking

More information

Resolution CM/Res(2016)2 on good reconstitution practices in health care establishments for medicinal products for parenteral use

Resolution CM/Res(2016)2 on good reconstitution practices in health care establishments for medicinal products for parenteral use Resolution CM/Res(2016)2 on good reconstitution practices in health care establishments for medicinal products for parenteral use (Adopted by the Committee of Ministers on 1 June 2016 at the 1258th meeting

More information

What is a reliable source of practical oncology stability data?

What is a reliable source of practical oncology stability data? What is a reliable source of practical oncology stability data? Pilar Blasco Chief Pharmacist, Valencia General Hospital, Spain Maria Cammarota Director of Pharmacy, Cardarelli Hospital, Naples, Italy

More information

Fresenius Investor News

Fresenius Investor News Analysts Meeting and Live video webcast today Fresenius Medical Care at 2.30 p.m. CET / 8.30 a.m. EDT Fresenius AG at 4.30 p.m. CET / 10.30 a.m. EDT health care worldwide May 4, 2005 Contact: Birgit Grund

More information

Pharmacy Compounding: Infection Prevention

Pharmacy Compounding: Infection Prevention Pharmacy Compounding: Infection Prevention Sam Eberwein, PharmD, MS, BCPS Clinical Manager, Sterile Products Area, Perioperative Services, & Special Formulations UNC Medical Center Department of Pharmacy

More information

Extractable and Leachable Challenges From a generic injectable drug development perspective

Extractable and Leachable Challenges From a generic injectable drug development perspective Extractable and Leachable Challenges From a generic injectable drug development perspective Andrea Redd Director, US Regulatory Affairs Fresenius Kabi November 8, 2017 Disclaimer This presentation contains

More information

How will you take control of your sterile compounding strategy? i.v.station

How will you take control of your sterile compounding strategy? i.v.station How will you take control of your sterile compounding strategy? i.v.station A safe, efficient, and cost-effective solution for sterile compounding The challenges of sterile compounding are real. Hospitals

More information

Company Presentation. September Frankfurt stock exchange: FRE US ADR program: FSNUY

Company Presentation. September Frankfurt stock exchange: FRE US ADR program: FSNUY Company Presentation September 2018 Frankfurt stock exchange: FRE US ADR program: FSNUY www.fresenius.com/investors Safe Harbor Statement This presentation contains forward-looking statements that are

More information

Fresenius Medical Care and Fresenius Kabi confirm guidance for 2009, Fresenius Helios and Fresenius Vamed raise their outlook

Fresenius Medical Care and Fresenius Kabi confirm guidance for 2009, Fresenius Helios and Fresenius Vamed raise their outlook Press Release August 4, 2009 Joachim Weith Senior Vice President Corporate Communications and Public Affairs Fresenius SE Else-Kröner-Straße 1 61352 Bad Homburg Germany T +49 6172 608-2101 F +49 6172 608-2294

More information

Quarterly Financial Report of Fresenius Group

Quarterly Financial Report of Fresenius Group Quarterly Financial Report of Fresenius Group applying International Financial Reporting Standards (IFRS) 1 st Half and 2 nd Quarter 2010 2 CONTENT 3 Fresenius Group figures at a glance 5 Fresenius shares

More information

NCCP GUIDANCE DOCUMENT DOSE BANDING FOR SYSTEMIC ANTICANCER THERAPY (SACT)

NCCP GUIDANCE DOCUMENT DOSE BANDING FOR SYSTEMIC ANTICANCER THERAPY (SACT) NCCP GUIDANCE DOCUMENT DOSE BANDING FOR SYSTEMIC ANTICANCER THERAPY (SACT) This is a draft document subject to agreement Version Date Amendment Approved By 1 05/04/16 Initial Draft 1 Table of Contents

More information

Automated compounding for intravenous chemotherapy

Automated compounding for intravenous chemotherapy Automated compounding for intravenous chemotherapy Not valid for printing! Low resolution PDF file. For high resolution files, please contact Communication & Image Dept. The correct preparation and administration

More information

Contract Manufacturing Services for Pre-filled Syringes

Contract Manufacturing Services for Pre-filled Syringes Contract Manufacturing Services for Pre-filled Syringes From Standard Solutions to Complex Products Stefan Czvitkovich, PhD Director Product Partnering Sterile Pharmaceuticals Central Europe CPhI woldwide

More information

Annual General Meeting of Fresenius SE & Co. KGaA on May 12, Speech of Stephan Sturm, Chairman of the Management Board

Annual General Meeting of Fresenius SE & Co. KGaA on May 12, Speech of Stephan Sturm, Chairman of the Management Board Annual General Meeting of Fresenius SE & Co. KGaA on May 12, 2017 Speech of Stephan Sturm, Chairman of the Management Board The spoken word has precedence. Dear Shareholders, Welcome to the Annual General

More information

Mercy - ROi. Success Story

Mercy - ROi. Success Story Mercy - ROi Success Story Our evaluation determined greater functionality was required to adequately support a fully integrated pharmaceutical distribution model. This conclusion led us to investigate

More information

Conference Call Q3/2016 Results

Conference Call Q3/2016 Results Conference Call Q3/206 Results Bad Homburg, 27 October 206 Frankfurt stock exchange: FRE US ADR program: FSNUY www.fresenius.com/investors Safe Harbor Statement This presentation contains forward-looking

More information

Fresenius Investor News

Fresenius Investor News health care worldwide August 3, 2006 Contact: Birgit Grund Fresenius AG Investor Relations Tel. ++49-6172 - 608 2485 Fax ++49-6172 - 608 2488 e-mail: ir-fre@fresenius.de Internet: www.fresenius-ag.com

More information

Analysis & Perspectives of the Different Systems and Uncovering Cost Impact of Various Systems

Analysis & Perspectives of the Different Systems and Uncovering Cost Impact of Various Systems Analysis & Perspectives of the Different Systems and Uncovering Cost Impact of Various Systems Christopher Fortier, PharmD, FASHP Chief Pharmacy Officer Massachusetts General Hospital RED SOX DECISION

More information

COMPOUND MEDICATION NON-FORMULARY (QUALIFIED HEALTH PLANS)

COMPOUND MEDICATION NON-FORMULARY (QUALIFIED HEALTH PLANS) COMPOUND MEDICATION NON-FORMULARY (QUALIFIED HEALTH PLANS) Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit

More information

Drug Products, Labeling, and Packaging

Drug Products, Labeling, and Packaging 442 Pharmaceutical Industry: Drug Products, Labeling, and Packaging Positions Drug Products, Labeling, and Packaging Ready-to-Administer Packaging for Hazardous Drug Products Intended for Home Use (1711)

More information

HSBC Healthcare Day. Frankfurt, 23 November Frankfurt stock exchange: FRE US ADR program: FSNUY

HSBC Healthcare Day. Frankfurt, 23 November Frankfurt stock exchange: FRE US ADR program: FSNUY HSBC Healthcare Day Frankfurt, 23 November 2017 Frankfurt stock exchange: FRE US ADR program: FSNUY www.fresenius.com/investors Safe Harbor Statement This presentation contains forward-looking statements

More information

Fresenius SE & Co. KGaA (FRE) - Medical Equipment - Deals and Alliances Profile

Fresenius SE & Co. KGaA (FRE) - Medical Equipment - Deals and Alliances Profile Fresenius SE & Co. KGaA (FRE) - Medical Equipment - Deals and Alliances Profile Fresenius SE & Co. KGaA (FRE) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business

More information

March 4, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

March 4, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852 March 4, 2014 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2013-N-1523: Request for Nominations: Drug Products that

More information

Meeting of the Minds: Pharmacy Services and Integration

Meeting of the Minds: Pharmacy Services and Integration Meeting of the Minds: Pharmacy Services and Integration RICK ABBOTT- B.Sc (Pharm) Regional Pharmacy Manager, Systemic Therapy, Eastern Health, Pharmacy Services CAROLE R. CHAMBERS- B.Sc (PHARM), MBA Pharmacy

More information

Cleaning validation of cleanrooms and preparation equipments

Cleaning validation of cleanrooms and preparation equipments Cleaning validation of cleanrooms and preparation equipments Dr Farshid SADEGHIPOUR Head of production Central Pharmacy, Geneva University Hospitals EAHP Foundation Seminar: Patient Safety; More About

More information

The use of advanced therapy medicinal products new competencies for hospital pharmacists

The use of advanced therapy medicinal products new competencies for hospital pharmacists The use of advanced therapy medicinal products new competencies for hospital pharmacists Seminar PH4 Anne Black Assistant Director of Pharmacy - Quality Assurance Disclosure Relevant Financial Relationships

More information

Biological contamination events in isolators: What lessons can be learned?

Biological contamination events in isolators: What lessons can be learned? WHITE PAPER SCIENCE DRIVEN BIO-DECONTAMINATION LS001-MKT-008 Rev 1US Biological contamination events in isolators: What lessons can be learned? James Drinkwater, Bioquell UK Process & Compliance Director.

More information

10/06/2016. Sustainable biosimilar policies. Panel discussion - Joint 22 nd Medicines for Europe and 19 th IGBA Annual Conference in Dubrovnik.

10/06/2016. Sustainable biosimilar policies. Panel discussion - Joint 22 nd Medicines for Europe and 19 th IGBA Annual Conference in Dubrovnik. Sustainable biosimilar policies Panel discussion - Joint 22 nd Medicines for Europe and 19 th IGBA Annual Conference in Dubrovnik June 9, 2016 Michael Dilger Matthias Liefner Mark Kastner Nicklas Jacobsen

More information

Pain Full Drug Shortages

Pain Full Drug Shortages Pain Full Drug Shortages Barbara Higgins, Pharm.D Assistant Director Pharmacy, Medication Use Systems University of Michigan Hospitals and Health System Ann Arbor, MI Objectives Describe actions taken

More information

Facts and Figures eople

Facts and Figures eople Facts and Figures 2012 eople The company The company Content 2 Sales in million The is an independent, owner-operated The company The at a glance 2 3 2012 highlights hameln rds 4 hameln pharma 5 hameln

More information

Excellent start into 2011 Fresenius raises 2011 sales and earnings outlook

Excellent start into 2011 Fresenius raises 2011 sales and earnings outlook Press Release May 4, 2011 Matthias Link Konzern-Kommunikation Fresenius SE & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg Germany T +49 6172 608-2872 F +49 6172 608-2294 Matthias.Link@fresenius.com

More information

Going Paperless Baxter MD - Full electronic Batch Record & Release with XFP SIMATIC IT. Answers for industry.

Going Paperless Baxter MD - Full electronic Batch Record & Release with XFP SIMATIC IT. Answers for industry. Going Paperless Baxter MD - Full electronic Batch Record & Release with XFP SIMATIC IT Answers for industry. Before we implemented XFP-MES at the Irish plant, the documentation department needed 3 to 4

More information

Global Sterile Liquid Capabilities

Global Sterile Liquid Capabilities Global Sterile Liquid Capabilities The life science business of Merck operates as MilliporeSigma in the U.S. and Canada. WHY US? Our Global Sterile Liquid capabilities are designed to enhance and streamline

More information

Gloveless Robotic Technologies in Aseptic. Personalized Cytotoxic. Association. Drugs. Sergio Mauri FEDEGARI GROUP

Gloveless Robotic Technologies in Aseptic. Personalized Cytotoxic. Association. Drugs. Sergio Mauri FEDEGARI GROUP Gloveless Robotic Technologies in Aseptic PDA: Manufacturing A Global for Personalized Cytotoxic Association Sergio Mauri FEDEGARI GROUP Drugs Presentation outline Pharma outlook trends and the aseptic

More information

Specialty Pharmacy 101

Specialty Pharmacy 101 Specialty Pharmacy 101 The Landscape of Specialty Pharmacy Services DATE: October 27, 2011 NAME: TITLE: Clinical Pharmacist, Serve You Agenda Define specialty pharmacy Examine market trends and current

More information

Capabilities Overview Presentation. Presenter

Capabilities Overview Presentation. Presenter Capabilities Overview Presentation Presenter About Baxter Global, diversified healthcare company 80 years of parenteral expertise driven by a well recognized global brand $12.6 billion global market leader

More information

Quarterly Financial Report of Fresenius Group

Quarterly Financial Report of Fresenius Group Quarterly Financial Report of Fresenius Group applying International Financial Reporting Standards (IFRS) 1 st Quarter 2015 2 TABLE OF CONTENTS 3 Fresenius Group figures at a glance 5 Fresenius share 6

More information

Using RFID for IV Pump Management

Using RFID for IV Pump Management Using RFID for IV Pump Management September 4, 2008 James Van Drasek System Director, Materials Management HealthEast Care System Strategies Clinical Advantage Strategy: Provide clinical care that exceeds

More information

Quarterly Financial Report of Fresenius Group

Quarterly Financial Report of Fresenius Group Quarterly Financial Report of Fresenius Group applying United States Generally Accepted Accounting Principles (U.S. GAAP) 1 st 3 rd Quarter and 3 rd Quarter 2011 2 CONTENT 3 Fresenius Group figures at

More information

Partner with the Global Leader in Drug Delivery Systems

Partner with the Global Leader in Drug Delivery Systems 3M DRUG DELIVERY SYSTEMS Partner with the Global Leader in Drug Delivery Systems Northridge, CA, USA Manufacturing Facility Experts at Commercializing Innovation 3M: Transforming New Ideas into Thousands

More information

NCCP GUIDANCE DOCUMENT DOSE BANDING FOR SYSTEMIC ANTICANCER THERAPY (SACT) Version Date Amendment Approved By 1 03/06/16 Version 1 Working Group

NCCP GUIDANCE DOCUMENT DOSE BANDING FOR SYSTEMIC ANTICANCER THERAPY (SACT) Version Date Amendment Approved By 1 03/06/16 Version 1 Working Group NCCP GUIDANCE DOCUMENT DOSE BANDING FOR SYSTEMIC ANTICANCER THERAPY (SACT) Version Date Amendment Approved By 1 03/06/16 Version 1 Working Group 1 Table of Contents Acknowledgements... 3 1 Background...

More information

FOCUS ON: Oncology Systems

FOCUS ON: Oncology Systems FOCUS ON: Oncology Systems Delivering Excellence Focused and committed In to Oconology helping you Infusion deliver Therapy From Preparation To Administration Excellence in Powerful medications used in

More information

1. POLICY STATEMENT: 2. BACKGROUND:

1. POLICY STATEMENT: 2. BACKGROUND: POLICY #: RCO-201 Page: 1 of 5 1. POLICY STATEMENT: All Food and Drug Administration (FDA) regulated research conducted under an Investigational New Drug Application (IND) and managed within DF/HCC requires

More information

Important Updates in USP <797> and USP <823> Eric S. Kastango, MBA, BS Pharm, FASHP Clinical IQ, LLC & CriticalPoint, LLC Madison, New Jersey

Important Updates in USP <797> and USP <823> Eric S. Kastango, MBA, BS Pharm, FASHP Clinical IQ, LLC & CriticalPoint, LLC Madison, New Jersey Important Updates in USP and USP Eric S. Kastango, MBA, BS Pharm, FASHP Clinical IQ, LLC & CriticalPoint, LLC Madison, New Jersey Disclosures Principal-Clinical IQ, LLC Healthcare consulting

More information

IT S WHAT YOU CAN T SEE THAT HURTS YOU IS THE PHARMACEUTICAL INDUSTRY REPLACING EXISTING MEDICATIONS WITH MORE EXPENSIVE MEDICATIONS?

IT S WHAT YOU CAN T SEE THAT HURTS YOU IS THE PHARMACEUTICAL INDUSTRY REPLACING EXISTING MEDICATIONS WITH MORE EXPENSIVE MEDICATIONS? SPECIALTY DRUGS Many plan sponsors have had to make difficult and painful choices about how to spend pharmacy benefit dollars But now payors are once again challenged not just by extremely high costs but

More information

12/10/2011. Development of sterile medicinal products in Dutch hospital pharmacy SEHP Santiago de Compostella. Introduction.

12/10/2011. Development of sterile medicinal products in Dutch hospital pharmacy SEHP Santiago de Compostella. Introduction. Development of sterile medicinal products in Dutch hospital pharmacy SEHP 2011 Santiago de Compostella Introduction Willem Meulenhoff (1971) Production Pharmacist at NV Organon (MSD) Head of the Production

More information

Introduction PART. 1 Why Technicians Need to Study Pharmacology and Therapeutics. 2 Pharmacokinetics

Introduction PART. 1 Why Technicians Need to Study Pharmacology and Therapeutics. 2 Pharmacokinetics PART Introduction 1 1 Why Technicians Need to Study Pharmacology and Therapeutics 2 Pharmacokinetics Understanding Pharmacology for Pharmacy Technicians 1 CHAPTER 1 Why Technicians Need to Study Pharmacology

More information